Skip to main content
. 2021 Feb 10;3(2):87–91. doi: 10.1016/j.bsheal.2021.02.001

Table 1.

Monoclonal antibodies currently ongoing phase 2, 3 and 4 trial.

Donor/ sponsor Product Clinical stage Trial ID Study
Regeneron Pharmaceuticals REGN10933 + REGN10987 combination therapy (Directed against RBD of S-protein of SARS-CoV-2) Phase 1/2 NCT04425629 2,014 ambulatory patients with COVID-19
Regeneron Pharmaceuticals REGN10933 + REGN10987 combination therapy (Directed against RBD of S-protein of SARS-CoV-2) Phase 1/2 NCT04426695 2,970 adult Hospitalized COVID-19 patients
Sorrento Therapeutics, Inc. COVI-AMG (mAb targeting S-protein epitope, specifically D614G variant) Phase 1/2 NCT04584697 50 SARS-CoV-2 RNA positive asymptomatic/mild symptomatic participants
University of Cologne/ZKS Koln/Boehringer Ingelheim human monoclonal antibody DZIF-10c Phase 1/2a NCT04631666 69 SARS-CoV-2 RNA negative and positive individuals
Swedish Orphan Biovitrum Emapalumab (Anti-interferon gamma mAB) or Anakinra (Interleukin-1 Receptor Antagonist) Phase 2 NCT04324021 54 hospitalized COVID-19 patients with respiratory distress and hyper inflammation
Assistance Publique - Hôpitaux de Paris Tocilizumab (Anti IL-6 mAB) Phase 2 NCT04331808 228 COVID-19 patients included in CORIMUNDO-19 cohort
CytoDyn, Inc. Leronlimab (CCR-5 receptor inhibitor) Phase 2 NCT04347239 390 hospitalized severe or critically ill COVID-19 patients
Kinevant Sciences GmbH/Roivant Sciences, Inc. Gimsilumab (mAb against GM-CSF) Phase 2 NCT04351243 227 with lung injury or ARDS secondary to COVID-19
Maria del Rosario Garcia de Vicuña Pinedo/Instituto de Investigación Sanitaria Hospital Universitario de la Princesa Sarilumab (human IgG1 mAb that inhibits IL-6 mediated signaling) Phase 2 NCT04357808 30 patients with moderate-severe COVID-19 infection
Implicit Bioscience/University of Washington IC14(antibody to CD14 pattern recognition receptor) Phase 2 NCT04391309 300 adult Hospitalized COVID-19 patients
Ospedale San Raffaele Mavrilimumab (mAb against GM-CSF receptor alpha) Phase 2 NCT04397497 50 participants hospitalized with COVID-19 induced pneumonia
CSL Behring Garadacimab, (Factor XIIa antagonist) Phase 2 NCT04409509 124 COVID-19 positive severe patients with interstitial pneumonia
Hospices Civils de Lyon Nivolumab (Anti-PD1 antibody) Phase 2 NCT04413838 120 SARS-CoV-2 positive hospitalized obese individual with risk of severe infection
Fibrogen Pamrevlumab (antibody against connective tissue growth factor) Phase 2 NCT04432298 130 acute COVID-19 hospitalized patients
Johns Hopkins University/ Novartis/ Socar Research SA/ Brigham and Women's Hospital Crizanlizumab (mAb that reduced inflammation by binding to p-selectin) Phase 2 NCT04435184 40 SARS-CoV-2 positive hospitalized acute COVID-19 patients
Assistance Publique - Hôpitaux de Paris/ Institut National de la Santé Et de la Recherche Médicale, France Tocilizumab (Anti IL-6 mAB) Phase 2 NCT04476979 120 COVID-19 patients included in the CORIMUNO-19 cohort
Rapa Therapeutics LLC/ Hackensack Meridian Health RAPA-501-Allo Phase 2 NCT04482699 88 hospitalized, severe, post-intubation COVID-19 patients
National Institute of Allergy and Infectious Diseases (NIAID) Risankizumab (IL-23 inhibiting mAb) Phase 2 NCT04583956 200 SARS-CoV-2 positive hospitalized adult patient
National Institute of Allergy and Infectious Diseases (NIAID) Lenzilumab (mAb targeting GM-CSF) Phase 2 NCT04583969 200 SARS-CoV-2 positive hospitalized adult patients
Eli Lilly and Company/AbCellera Biologics Inc./ Shanghai Junshi Bioscience Co., Ltd. LY3819253 or LY3819253 + LY3832479 (mAB targeting S-protein epitope) Phase 2 NCT04634409 500 non-hospitalized mild to moderate COVID-19 patients
Assistance Publique - Hôpitaux de Paris Sarilumab (human IgG1 mAb that inhibits IL-6 mediated signaling) Phase 2/3 NCT04324073 239 COVID-19 patients included in CORIMUNO-19 cohort
I-Mab Biopharma Co. Ltd. TJ003234 (Anti-GM-CSF mAb) Phase 2/3 NCT04341116 384 severe COVID-19 patients under supportive care
Eli Lilly and company/ AbCellera Biologics Inc./Shanghai Junshi Bioscience Co., Ltd. LY3819253 and LY3832479 (mAb targeting S-protein epitope) Phase 2/3 NCT04427501 2,450 participants with mild to moderate COVID-19 illness
Alexion Pharmaceuticals Ravulizumab (prevent activation of complement component-5) Phase 3 NCT04369469 270 hospitalized COVID-19 patients with severe pneumonia, acute lung injury, or ARDS
Regeneron Pharmaceuticals REGN10933 + REGN10987 (mAB targeting S-protein epitope) Phase 3 NCT04452318 2,000 participants including household contacts of COVID-19 patients
Brigham and Women's Hospital Ravulizumab (mAb targeting C5 complement inhibition) Phase 3 NCT04570397 32 SARS-CoV-2 positive patients with thrombotic microangiopathy
AstraZeneca/QuintilesIMS AZD7442 (combination of AZD8895 and AZD1061 targeting S-protein of SARS-CoV-2) Phase 3 NCT04625725 5,000 participants as pre-exposure prophylaxis
AstraZeneca/QuintilesIMS AZD7442(combination of AZD8895 and AZD1061 targeting S-protein of SARS-CoV-2) Phase 3 NCT04625972 1,125 participants with exposure history within preceding 8 days
Hadassah Medical Organization/ Sheba Medical Center/ Wolfson Medical Center Tocilizumab (Anti IL-6 mAb) Phase 4 NCT04377750 500 participants with severe COVID-19 disease and suspected hyper-inflammation
Cambridge University Hospitals NHS Foundation Trust Ravulizumab (prevent activation of complement component-5) + Baricitinib (acts as inhibitor of janus kinase) Phase 4 NCT04390464 1,167 SARS-CoV-2 positive hospitalized pre-ICU patients